Where we work

You can zoom in on the map to see where we work in your region, and select a country to find out more.

We focus on access to affordable medicines in middle-income countries (MICs). Less than a third of the people in need of HIV treatment in MICs are currently able to access it, and it is a similar story when it comes to essential, optimal treatment for Hepatitis C and TB.

By 2020, the vast majority of people living with HIV (87%) will be in high- and middle-income countries. A sustainable response to HIV, Hep C and TB will not be possible without tackling the intellectual property (IP) barriers preventing access to medcines.